Your browser doesn't support javascript.
loading
Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
Lin, Shanshan; Tu, Guihui; Yu, Zelei; Jiang, Qingna; Zhang, Lingyu; Liu, Jingwen; Liu, Quanyu; Huang, Xiuwang; Xu, Jianhua; Lin, Youwen; Liu, Yang; Wu, Lixian.
Afiliación
  • Lin S; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, PR China.
  • Tu G; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.
  • Yu Z; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.
  • Jiang Q; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.
  • Zhang L; Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350001, PR China; Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350001, PR China.
  • Liu J; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.
  • Liu Q; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.
  • Huang X; Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, PR China; Department of Public Technology Service Center, Fujian Medical University (FMU), Fuzhou, PR China.
  • Xu J; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.
  • Lin Y; Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China. Electronic address: linhumor@fjmu.edu.cn.
  • Liu Y; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China; Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China. Electronic address: liuyang@fjmu.edu.cn.
  • Wu L; Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China. Electronic address: wlx-lisa@126.com.
Bioorg Med Chem ; 70: 116912, 2022 09 15.
Article en En | MEDLINE | ID: mdl-35830778
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferones / Nucleotidiltransferasas Límite: Humans Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferones / Nucleotidiltransferasas Límite: Humans Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido